Ensysce Biosciences Q3 2026 Results: Net Loss of $82.1M, Loss Widens
Ensysce Biosciences reported a significant net loss of $88.2 million for the nine months ended September 30, 2026, primarily driven by a $79.9 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity position, ending the period with $29.7 million in cash following multiple preferred stock and PIPE financing transactions.
- Key figure
- Net loss $82.1M